Clinical Trial Update: Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 feasibility trial evaluating adjuvant enzalutamide for early-stage androgen receptor-positive triple-negative breast cancer; the study is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer, Early Stage | Phase 2 | Status: ACTIVE_NOT_RECRUITING